NIH Awards UMD $427,625 R21 Grant to Develop PROTACs for Leukemia

Steven Fletcher, PhD, at the University of Maryland School of Pharmacy, has secured a $427,625 R21 grant from the National Institutes of Health to develop targeted therapies for aggressive leukemia.

The two-year project aims to bypass drug resistance by using PROTAC technology to degrade the menin protein, a primary driver of cancer growth.

  • Targeting the Driver: Instead of blocking the menin protein, researchers are designing molecules to remove it entirely from the cell.
  • Overcoming Resistance: This method seeks to prevent the cancer from “learning” how to ignore medication, a common hurdle in current leukemia therapies.
  • Pediatric Focus: Because this strategy targets specific cancer mechanisms rather than all rapidly dividing cells, it may offer a safer profile for infant patients.

The National Cancer Institute award, announced on November 20, 2026, supports a two-year investigation into KMT2A-rearranged leukemias. According to the UMSOP Office of Communications and Marketing, these specific cancers represent approximately 10 percent of adult acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL) cases, and roughly 80 percent of infant leukemia diagnoses. Despite modern advancements, the five-year survival rate for these populations remains at 35 percent.

The research relies on Proteolysis-Targeting Chimeras, known as PROTACs. “Instead of just inhibiting menin, which proceeds through occupancy-driven pharmacology, we are proposing to completely degrade the protein by hijacking the cell's ubiquitin-proteasome protein degradation system with engineered bifunctional molecules called PROTACs,” Fletcher, a professor in the Department of Pharmaceutical Sciences, said.

If a mutation changes the shape of the target, the inhibitor loses its effectiveness. By utilizing “event-driven pharmacology,” the new PROTAC molecules will instead hijack the cell’s own disposal system—the ubiquitin-proteasome pathway—to eliminate the menin protein entirely.

“Current small-molecule inhibitors targeting menin have demonstrated promising activity, but resistance can develop. Our approach is different. Rather than inhibiting the protein, we aim to harness the cell’s own protein degradation machinery to completely remove menin, said Fletcher.”

The project is a multi-principal investigator collaboration between Fletcher and Curt Civin, MD, a pediatric oncologist at the University of Maryland School of Medicine. The partnership integrates medicinal chemistry with leukemia biology to evaluate compounds from both chemical and clinical perspectives. The proposal earned a perfect impact score during the NIH peer-review process, a rare achievement that signals high scientific confidence in the methodology.

Steven Fletcher has built his career at the intersection of computer-aided drug design and chemical innovation, focusing on re-engineering existing therapies to overcome clinical resistance.

His work emphasizes the development of first-in-class inhibitors and the pioneering of molecular glues, a strategy designed to address the high molecular weight challenges often associated with traditional degradation technologies. By installing electrophilic warheads into ligands, Fletcher aims to create novel pathways for targeting proteins that have historically proven difficult to treat.

Strategy Mechanism Resistance Risk
Conventional Small-Molecule Inhibitors Occupancy-driven (blocking) High (via mutations)
PROTAC Molecules Event-driven (degradation) Potential for reduction

This research remains in the preclinical discovery phase.

  • The National Institutes of Health (NIH) awarded a two-year, $427,625 R21 grant to Steven Fletcher for research into novel leukemia treatment strategies.
  • The University of Maryland School of Pharmacy announced that Steven Fletcher and Curt Civin received a two-year, $427,625 NIH grant to develop targeted therapies for aggressive leukemia.
Photo of author

Health Desk

Health Desk at Archyde.

Italy spends an average of €6,300 per resident on pensions